Market News

Status marks the company as the first multi-site excipient supplier to achieve global EXCiPACT accreditation across its production facilities.

Kit increases efficiency of residual protein A ligand detection.

Goldfinch Bio’s researchers select StarDrop to guide successful drug discovery.

Xermelo is a first-in-class orally administered therapy for the treatment of carcinoid syndrome diarrhea.

Highly precise dosing of smallest amounts of API.

Inside Rx, a new initiative from Express Scripts, partners with GoodRx, drug manufacturers and drug stores to save Americans an average of 34% at 40,000 pharmacies

A key focus on Cherwell’s Stand A49 will be the microbiology requirements for pharmacy aseptic manufacturing, preparation and dispensing.

New ProSolus commercial team will provide potential partners throughout the pharmaceutical industry direct access to the state-of-the-art research, development, and manufacturing capabilities.

Company will be responsible for the GMP preparation and filling of AB569 into glass vials.

This chemistry testing offer complements the company’s existing range of off-the-shelf biological assays for biosimilar products, providing a complete solution from one contract partner.

Combined expertise is likely to have a significant impact in reducing the costs and complexity of ophthalmic clinical trials.

Library claimed to offer "the most efficient route to therapeutic antibody lead identification".

Expansion doubles manufacturing capacity and includes the introduction of new facilities.

Site is also expected to house production of a new subcutaneous form of belimumab, which is currently under review with the FDA.

P-321 is a Phase II investigational topical treatment for dry eye disease.

One of the first companies to offer a generic version of Vytorin.

New generation of bioreactors combined with new Flexsafe STR bags offer a fully scalable, single-use system.

Acquisition adds best-in-class body contouring business to Allergan's facial aesthetics, plastic surgery and regenerative medicine businesses.

Zenith Technologies surpasses the €20 million milestone for sales of its manufacturing execution system (MES) services.

System allows tablet manufacturers to keep a record of tablet quantities by number of tablets, work order or batch information to ensure production is run efficiently.

Company has also installed a high pressure, precision roller compactor to further support the development of spray-dried dispersions.

Transactions provide access to attractive pharmaceutical growth markets.

Formulations can be delivered as spray, drop, solution, medical wipe or dermal patch.and offer non-touch applications.

Novartis and Amgen to co-commercialize AMG 334 (erenumab) in the US; Novartis to gain exclusive rights in Canada,

First live demo of PLG’s powerful new AI-based social media listening solution, PLG inVolv, designed to help life sciences firms meet their pharmacovigilance obligations.

Significant investments in Bensheim headquarters; consistent portfolio additions; cleanroom expansion in China.

The $750k investment is intended to produce CTM for clinical studies up to Phase II for non-sterile dosage forms, including metered dose inhalers and semi-solid topical products.

Company has invested €300,000 into the project, which is part of a wider €40 million investment into new serialisation technology and processes to comply with the European Falsified Medicines Directive.

Website can help inform global health strategies to mitigate the threat of antimicrobial resistance.

An investment of more than 2 million euro over 3 years is planned to launch new events and resources.

Finneran bringing glass, plastics and assembly manufacturing capabilities and strong US distribution.

Merck is opening its compound library to DNDi to help find cures for leishmaniasis and Chagas disease.

Combined company well capitalized with $90 million in funding to advance discovery and development.

$130M USD investment to support growing market demand.

Increases Cardinal Health's product breadth in consumable medical products.

Capacity increase in response to customer demand for DNA and viral vector production.

Collaboration focused on Phase 2II clinical trial to evaluate use of Allergan's Cenicriviroc and Novartis' lead FXR agonist to treat NASH.

Two separate agreements with Biogen and Roche.

Efficient alternative to distillation.

Study to evaluate potential of APX005M plus Opdivo to activate antigen-presenting cells in the tumour micro-environment to demonstrate enhanced anti-tumour activity.

Henrik Stenqvist will be based at the company's HQ in Sweden.

Collaboration to advance oral microbial consortia products developed by using NuBiyota’s microbiome platform for GI indications.

Drug discovery software specialists combine expertise to extend studies into drug metabolism modelling.

Industry leading further education programs unified and expanded.

Company has achieved an annual energy intensity improvement of more than 3% globally, contributing to an 11.4% reduction in energy consumption since 2010.

Bosch showcases i4.0 solutions live at Interpack.

Agreement terms are "favourable for both parties".

ECF843 is a new therapeutic approach and potential first-in-class Rx treatment in dry-eye.

RedHill expects to initiate US promotion of its two commercially-available gastrointestinal specialty products, Donnatal and EnteraGam, in mid-2017.

Greater filtration capacity with a smaller footprint than conventional filters, improving economics for biopharmaceutical manufacturing.

First launch of product using FOX smart nebuliser.

David Meeker will leave the company at the end of June after a 23-year career with Genzyme and Sanofi.

The five-fold increase in capacity reflects growing demand for cold chain services.

Kit for confirming successful antibody-biotin conjugation.

Company's CAPA addresses the three Form 483 observations.

Will fund a new manufacturing, packaging and distribution facility.

Represents the latest combination therapy now available for the millions of patients living with COPD in the US.

New magnetic resonance technologies and applications open new frontiers for biological, chemical and materials research and routine analysis in pharmaceutical and chemical industries.

Recall will extend to additional markets in Europe, Asia, North and South America.

Installation of state-of-the-art Harro Hӧfliger encapsulation unit expands clinical- and commercial-scale capacity for dry powder inhalation applications.

ImpactAir high performance air sampler range joins Cherwell’s portfolio of cleanroom microbiology products.

Inspection of up to 600 glass containers per minute using unique group testing.

Cold-EEZE is now Mylan's largest US consumer healthcare brand.

Part of a longer term plan to increase capacity.

Offers more flexibility, better supply predictability and shorter lead times for more efficient and safer drug manufacture.

System can achieve separations with higher resolution, reproducibility and recovery then has previously been possible.

Canada first country to launch Fiasp.

Provides a cleaner, renewable energy source to reduce costs and lessen the CRO facility's impact on the environment.

First NCE approved for PD patients with motor fluctuations in the US in more than a decade .

Significant investment in manufacturing diabetes medicines continues with new $85 million commitment in Indianapolis.

More than 80 contract manufactures were assessed by 26 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey.

Developments correspond to generic products based on specialized pharmaceutical technologies.

Partnership to collaborate with industry to reduce risk and ensure optimal compliance for all members of the pharmaceutical supply chain.

New site will be used to complete premium injectable elastomeric component manufacturing.

The two new systems offer faster method development and the ability to quantify multiple proteins simultaneously.

PharmaCote ECxtra eliminates problems encountered during the hard chromium coating process.

5800-m2 facility will provide a range of GMP pharmaceutical testing services.

CDMO will manufacture and deliver Emla Patch - a local anaesthetic product.

TLE400 is a fixed-combination containing Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg.

Greater filtration capacity with a smaller footprint than conventional filters, improving economics for biopharmaceutical manufacturing.

Amgen has announced that the 27,564-patient Repatha (evolocumab) cardiovascular outcomes study, FOURIER, established for the first time that maximally reducing low-density lipoprotein cholesterol (LDL-C) levels with Repatha, beyond what is possible wit...

PIC/S membership accelerating international interest with market forecast to reach US$115bn by 2024.

The Xelum platform combines dosing, mixing, granulating and pressing, paving the way for more efficient tablet manufacturing.

Cinryze is the first and only Hereditary angioedema treatment approved for routine prevention in paediatrics.

Supports small molecule ion channel drug discovery, from initial screening to development candidate.

For success in the biosimilars sector, manufacturers must adopt QbD, DoE and PAT initiatives.

Alliance brings together eye care and CRISPR innovators to develop transformative medicines for patients.

Zavicefta treat complicated infections caused By Gram-negative bacteria.

Current product portfolio includes a range of specialty alkoxide bases and borane derivatives.

Settlement provides Mylan with global licenses for its trastuzumab product.

Work on a second-generation fusion protein due to start in 2017 at Patheon's manufacturing facility in Brisbane.

The tablets are indicated for the treatment of major depressive disorder.

Collaboration is the second to evaluate a combination of CV301 with a checkpoint inhibitor.

Tooling products focused on increasing productivity for the tablet manufacturer.

Partnership formed to evaluate the impact of Amplycell’s novel cell fitness technology on expression capacity of Horizon’s bioproduction cell line.

Expansion plan comprises company's largest investment in the US.

The multi-site installations support a variety of drug delivery forms, including bottles, unit cartons and parenteral kits, as well as unit dose wallets and child resistant/compliance prompting packaging.

He succeeds Dr Francis Cuss, 62, who will retire from the company.

Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF.

Alcami will use the D8 DISCOVER HTS to add XRD capabilities to their laboratory service portfolio.

Merck's €42 million investment expands the allergies business on a global scale.

MEDI8897 has been engineered to have a long half-life so that only one dose would be needed for the entire RSV season.

Reinforces position as a supplier of excipients and raw materials for the pharmaceutical and biopharmaceutical industries.

Funding will be used to prepare for international clinical study to evaluate the Company’s ELISA-based urine test for prostate cancer.

Affinivax’s MAPS vaccine technology overcomes the limitations of current conjugate vaccine technology, creating a MAPS pneumococcal vaccine that enables broader protection.

Government plans to construct 10 factories for the manufacturing of biosimilars by 2020, with an additional investment of $265.3 million.

Acquisition enhances Lilly's existing pain management.

Innovation is being driven increasingly by smaller, possibly more agile, companies.

Supports a wide range of needs across the biopharma development cycle.

New model incorporates an improved algorithm to simplify test creation and accelerate test completion.

Partnership leverages Lonza's expertise in large-scale mammalian cell culture facilities alongside Sanofi's strength in developing and launching biologics based treatments.

Recall due to potential lack of sterility assurance.

Tool explores the time course of drug exposure, biomarker response and outcome.

Portfolio includes treatments for Crohn's disease, ulcerative colitis, and bowel preparation before endoscopy.

Approval of the automated mini-doser marks first hands-free administration option for a PCSK9 inhibitor in Europe.

Aids R&D initiatives to advance precision medicine.

EP Vantage Releases its Annual Pharma and Medtech Sector Review Reports for 2016.

New kit enables covalent conjugation of antibodies and proteins to magnetic particles.

The acquired business is now known as Recipharm Pharmaservices Private Ltd.

Distributors, API manufacturers, and machinery providers seeing high demand across Russia and CIS.